Real-World Screening Data for Liver Fibrosis in Psoriasis Patients Treated with Biologics.

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is positively associated with the prevalence and severity of psoriasis. The fibrosis-4 (FIB-4) index was developed to predict significant liver fibrosis. Using the FIB-4 index, the present study evaluated screening data for liver fibrosis, including MASLD, in patients with refractory psoriasis treated with biologics.

Identification of Early and Late Responders to Anti-IL-13 Antibody Tralokinumab in Atopic Dermatitis: A Real-World Japanese Study.

Tralokinumab, an anti-IL-13 antibody, is an effective treatment for patients with atopic dermatitis (AD). However, predictive factors for responders to tralokinumab remain unclear in real-world practice. This study aimed to identify predictive factors for early and late responders to tralokinumab treatment.

Predictive factors for responders to deucravacitinib treatment in patients with psoriasis.

The tyrosine kinase 2 inhibitor deucravacitinib is therapeutically effective for psoriasis. However, predictive factors for high responses to deucravacitinib have not been examined in a real-world clinical study. Our study aimed to identify predictive factors for responders to deucravacitinib.

Risk Factors for Long-Term Nutritional Disorders One Year After COVID-19: A Post Hoc Analysis of COVID-19 Recovery Study II.

: COVID-19 patients develop various clinical symptoms, including malnutrition. However, the risk factors for long-term nutritional disorders remain unclear. Identifying these factors is crucial for preventing nutritional disorders by initiating early nutritional interventions.

Long-term effectiveness and safety of deucravacitinib in psoriasis: A 52-week real-world study of genital, scalp, and nail lesions.

Background: The long-term (around 1-year) effectiveness and safety of deucravacitinib for the treatment of psoriasis have not been extensively studied in real-world settings, particularly in difficult-to-treat areas, such as the genital, scalp, and nail regions.

Objectives: To evaluate the 52-week real-world effectiveness and safety of deucravacitinib in patients with moderate-to-severe psoriasis of the genital, scalp, and nail regions.

Methods: This prospective study analyzed 104 patients with moderate-to-severe plaque psoriasis treated with deucravacitinib.